Innovative Therapies for Children with Cancer in Europe

2012

Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.

Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socié G, Méchinaud F, Doz F, Neven B, Bertrand Y, Galambrun C, Demeocq F, Yakouben K, Bordigoni P, Frappaz D, Nguyen L, Vassal G.

Pediatr Blood Cancer. 2012 Jan;58(1):90-7. doi: 10.1002/pbc.22959. Epub 2011 Jan 19.

Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.

Doussau A, Asselain B, Le Deley MC, Geoerger B, Doz F, Vassal G, Paoletti X.

Contemp Clin Trials. 2012 Jul;33(4):657-65. Epub 2012 Apr 13.

2010
Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study.

Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJ; International BFM Study Group on Paediatric AML.
Br J Haematol. 2010 Mar;148(5):768-76. Epub 2009 Dec 8.

Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.

Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA; ALLNA 2008 Conference.
Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8.

2008

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Höglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY.

Blood. 2008 Aug 15;112(4):1005-12. Epub 2008 May 13.

Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.

Vassal G, Michel G, Espérou H, Gentet JC, Valteau-Couanet D, Doz F, Mechinaud F, Galambrun C, Neven B, Zouabi H, Nguyen L, Puozzo C.
Cancer Chemother Pharmacol. 2008 Jan;61(1):113-23. Epub 2007 Mar 29.